Clinical Trial

ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated January 16, 2025 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.
Summary
A Phase 3, Randomized, Double-Arm, Open-Label, Controlled Trial of ASP-1929 vs Physician's Choice Standard of Care for the Treatment of Locoregional, Recurrent Head and Neck Squamous Cell Carcinoma in Patients Who Have Failed or Progressed On or After at Least Two Lines of Therapy
Protocol Amendment History 19 amendments
This ClinicalTrials.gov record has been amended 19 times since 2018-12-06; most recent amendment 2025-01-14.
Status change: Recruiting → Active, Not Recruiting 2025-01-14
Status change: Not Yet Recruiting → Recruiting 2019-02-07
Status change: Withheld → Not Yet Recruiting 2018-12-28
Trial Details
NCT Number NCT03769506
Lead Sponsor Rakuten Medical, Inc.
Conditions Head and Neck Cancer
Enrollment 135 participants
Start Date 2019-05-09
Primary Completion 2025-12 (estimated)
Study Completion 2025-12 (estimated)
Updated on ClinicalTrials.gov 2025-01-16